Amgen’s experimental drug dazodalibep met its main goals in a Phase 3 trial for Sjögren’s disease — a common autoimmune condition that, remarkably, still has no FDA-approved treatment. For up to four million Americans, that gap may finally be starting to close.

The disease

Sjögren’s (pronounced “SHOW-grins”) is the second most common rheumatic autoimmune disease, affecting up to 4 million Americans. In it, the immune system mistakenly attacks the body’s moisture-producing glands — chiefly the tear ducts and salivary glands — causing hallmark dry eyes and dry mouth, along with fatigue and joint pain. Though often dismissed as merely uncomfortable, it can be genuinely debilitating, and its systemic effects reach beyond dryness. Until now, treatment has meant managing symptoms, not the disease itself.

How dazodalibep works

Dazodalibep is a fusion protein engineered to block CD40 ligand (CD40L) — a molecule immune cells use to communicate and coordinate attacks. By disrupting that CD40L signaling, the drug aims to dial down the misguided immune response driving the gland damage, rather than just soothing the dryness it causes. It’s a targeted, mechanism-based approach to an autoimmune disease that has resisted them.

The trial results

Preliminary Phase 3 results met both primary and secondary endpoints with what the company called “statistically significant and clinically meaningful” results. Encouragingly, improvement appeared as early as week 4 and was sustained through week 48, across measures of disease activity including dryness, joint involvement and fatigue. Side effects were generally mild to moderate — the most common being nasopharyngitis, urinary tract infections, hypertension and infusion-related reactions. “The results provide further support for dazodalibep as an emerging treatment for improving systemic disease activity,” said Dr. Ghaith Noaiseh.

A competitive moment

Amgen isn’t alone in racing to fill this void. Novartis’s ianalumab, an antibody targeting the BAFF receptor, is already under FDA review and could become the first approved Sjögren’s therapy. After decades with nothing, patients may soon have multiple options — a striking turnaround for a neglected disease and a sign that autoimmune drug development is reaching conditions long left behind.

Why it matters — and the caveats

A first-ever approved treatment would be meaningful for millions living with a disease that erodes quality of life. But context is warranted: these are preliminary Phase 3 results, and Amgen withheld the specific data for presentation at a future medical conference, so the full picture — including the magnitude of benefit — awaits scrutiny. A second Phase 3 trial in patients with high symptom burden could finish in late 2026. Positive top-line results are a strong step, not an approval. This is business and clinical news, not medical advice.